Chua Kim Leng
co-founder, advisor 

Kim Leng is a board director of several listed companies and financial institutions. An industry veteran, he had an enriching 25-year career with the Monetary Authority of Singapore (MAS). His previous role with the MAS was Special Advisor (Financial Supervision) and prior to that Assistant Managing Director of the Banking & Insurance Group, responsible for the licensing and supervision of banks and insurance companies.


Kim Leng was awarded the Public Administration Medal in 2014 by the President of Singapore for outstanding efficiency, competence and industry.

Untitled design.png
Dr Tan Kok Heng 

Dr Tan Kok Heng serves as the Executive Director of Sunway RE Capital Pte Ltd, the real estate investment management arm of Sunway Berhad.


Dr Tan oversees the real estate fund management business with the objective of building Sunway’s overseas property business and growing its recurring income. His responsibilities include deal origination and fund raising, with the emphasis of setting up listed and unlisted funds.


Prior to Sunway, Dr Tan was the CEO of Fund Management Business and Chief Investment Officer of Sime Darby Property Berhad (“SDPB”). He was instrumental in setting up several private real estate and development funds for SDPB, as well as being involved in numerous joint ventures. Before his appointment at SDPB, he held various executive appointments, with Colliers International (Singapore) Pte Ltd) and CapitaLand Limited.


Dr Tan graduated from the National University of Singapore with a Bachelor of Science (Hons) in Estate Management. He also holds a Graduate Diploma in Financial Management from the Singapore Institute of Management, Master of International Business from the Curtin University of Technology, Australia and Doctorate (Transdisciplinary Studies) from Central Queensland University, Australia. He is also a member of the Singapore Institute of Directors.

joshua liu

Joshua's 20+ years of experience in the investment banking and securities industry has equipped him with expertise in handling a broad range of financial advisory transactions.


Concurrent to being an advisor for ternary, he is the Managing Director and principal supervisor for IPOs in Lego Corporate Finance, a listed entity in Hong Kong (3938HK). 


Joshua has managed numerous IPOs, including Best Mart 360 (2360HK), Prosper One (1470HK), SFund International (1367HK), and K Group Holdings (8475HK) and previously worked with established corporate finance houses in Hong Kong, such as Optima Capital Limited, South China Capital Limited and Pacific Challenge Capital Limited.


Joshua graduated from Hong Kong Baptist University with a Bachelor’s Degree in Business Administration (Major in Management Information Systems).

Yang Yan

Elina's experience in IPO consulting and M&A advisory in China and Hong Kong stems from her time as Deputy General Manager of Guanxi Guijiang Co. Ltd, a Guangxi government owned company in Hong Kong.

She served as manager of the Central Business Development Department with Deloitte China, where she was responsible for establishing the Guangxi Industrial fund and providing consulting and tax advisory services for Nanning Rail Transit Co. Ltd. 

Elina started her career in capital markets with Sealand Securities Co. Ltd, followed by Chinalin Securities Co. Ltd where she provided investment analyses, managing portfolios, developing marketing channels as well as managing compliance and risk control. 

Elina graduated with a MBA from Guangxi University.

gordon tsang

Gordon is a Senior Associate of Stevenson, Wong & Co. He was admitted to practice as a solicitor in Australia in 2012 and in Hong Kong in 2013.


Gordon has experience in handling a wide range of corporate and commercial matters, including pre-IPO restructuring and financing, Hong Kong and U.S. IPOs, mergers and acquisitions and general compliance for listed companies.


Gordon is the Non-Executive Director of China Regenerative Medicine International Ltd (Stock Code: 8158); he is also the Company Secretary of Sunshine 100 China Holdings Ltd (Stock Code: 2608) and Mabpharm Limited-B (Stock Code: 2181).